Literature DB >> 33435983

An ensemble learning approach for modeling the systems biology of drug-induced injury.

Joaquim Aguirre-Plans1, Janet Piñero1, Terezinha Souza2, Giulia Callegaro3, Steven J Kunnen3, Ferran Sanz1, Narcis Fernandez-Fuentes4,5, Laura I Furlong1, Emre Guney1, Baldo Oliva6.   

Abstract

BACKGROUND: Drug-induced liver injury (DILI) is an adverse reaction caused by the intake of drugs of common use that produces liver damage. The impact of DILI is estimated to affect around 20 in 100,000 inhabitants worldwide each year. Despite being one of the main causes of liver failure, the pathophysiology and mechanisms of DILI are poorly understood. In the present study, we developed an ensemble learning approach based on different features (CMap gene expression, chemical structures, drug targets) to predict drugs that might cause DILI and gain a better understanding of the mechanisms linked to the adverse reaction.
RESULTS: We searched for gene signatures in CMap gene expression data by using two approaches: phenotype-gene associations data from DisGeNET, and a non-parametric test comparing gene expression of DILI-Concern and No-DILI-Concern drugs (as per DILIrank definitions). The average accuracy of the classifiers in both approaches was 69%. We used chemical structures as features, obtaining an accuracy of 65%. The combination of both types of features produced an accuracy around 63%, but improved the independent hold-out test up to 67%. The use of drug-target associations as feature obtained the best accuracy (70%) in the independent hold-out test.
CONCLUSIONS: When using CMap gene expression data, searching for a specific gene signature among the landmark genes improves the quality of the classifiers, but it is still limited by the intrinsic noise of the dataset. When using chemical structures as a feature, the structural diversity of the known DILI-causing drugs hampers the prediction, which is a similar problem as for the use of gene expression information. The combination of both features did not improve the quality of the classifiers but increased the robustness as shown on independent hold-out tests. The use of drug-target associations as feature improved the prediction, specially the specificity, and the results were comparable to previous research studies.

Entities:  

Keywords:  CAMDA; Cmap; Drug safety; Drug structure; Drug-induced liver injury; Hepatotoxicity; Machine learning; Systems biology

Year:  2021        PMID: 33435983      PMCID: PMC7805064          DOI: 10.1186/s13062-020-00288-x

Source DB:  PubMed          Journal:  Biol Direct        ISSN: 1745-6150            Impact factor:   4.540


  38 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  RxnSim: a tool to compare biochemical reactions.

Authors:  Varun Giri; Tadi Venkata Sivakumar; Kwang Myung Cho; Tae Yong Kim; Anirban Bhaduri
Journal:  Bioinformatics       Date:  2015-07-17       Impact factor: 6.937

Review 3.  Applications of machine learning in drug discovery and development.

Authors:  Jessica Vamathevan; Dominic Clark; Paul Czodrowski; Ian Dunham; Edgardo Ferran; George Lee; Bin Li; Anant Madabhushi; Parantu Shah; Michaela Spitzer; Shanrong Zhao
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

Review 4.  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Authors:  Minjun Chen; Ayako Suzuki; Shraddha Thakkar; Ke Yu; Chuchu Hu; Weida Tong
Journal:  Drug Discov Today       Date:  2016-03-03       Impact factor: 7.851

5.  Disease networks. Uncovering disease-disease relationships through the incomplete interactome.

Authors:  Jörg Menche; Amitabh Sharma; Maksim Kitsak; Susan Dina Ghiassian; Marc Vidal; Joseph Loscalzo; Albert-László Barabási
Journal:  Science       Date:  2015-02-20       Impact factor: 47.728

6.  Relating protein pharmacology by ligand chemistry.

Authors:  Michael J Keiser; Bryan L Roth; Blaine N Armbruster; Paul Ernsberger; John J Irwin; Brian K Shoichet
Journal:  Nat Biotechnol       Date:  2007-02       Impact factor: 54.908

7.  The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study.

Authors:  Abhasnee Sobhonslidsuk; Kittiyod Poovorawan; Ngamphol Soonthornworasiri; Wirichada Pan-Ngum; Kamthorn Phaosawasdi
Journal:  BMC Gastroenterol       Date:  2016-10-28       Impact factor: 3.067

Review 8.  Drug-induced liver injury: recent advances in diagnosis and risk assessment.

Authors:  Gerd A Kullak-Ublick; Raul J Andrade; Michael Merz; Peter End; Andreas Benesic; Alexander L Gerbes; Guruprasad P Aithal
Journal:  Gut       Date:  2017-03-23       Impact factor: 23.059

9.  Deep Neural Network Models for Predicting Chemically Induced Liver Toxicity Endpoints From Transcriptomic Responses.

Authors:  Hao Wang; Ruifeng Liu; Patric Schyman; Anders Wallqvist
Journal:  Front Pharmacol       Date:  2019-02-05       Impact factor: 5.810

10.  DGIdb 3.0: a redesign and expansion of the drug-gene interaction database.

Authors:  Kelsy C Cotto; Alex H Wagner; Yang-Yang Feng; Susanna Kiwala; Adam C Coffman; Gregory Spies; Alex Wollam; Nicholas C Spies; Obi L Griffith; Malachi Griffith
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  2 in total

1.  An Algorithm Framework for Drug-Induced Liver Injury Prediction Based on Genetic Algorithm and Ensemble Learning.

Authors:  Bowei Yan; Xiaona Ye; Jing Wang; Junshan Han; Lianlian Wu; Song He; Kunhong Liu; Xiaochen Bo
Journal:  Molecules       Date:  2022-05-12       Impact factor: 4.927

2.  The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and Perspectives.

Authors:  François Pognan; Thomas Steger-Hartmann; Carlos Díaz; Niklas Blomberg; Frank Bringezu; Katharine Briggs; Giulia Callegaro; Salvador Capella-Gutierrez; Emilio Centeno; Javier Corvi; Philip Drew; William C Drewe; José M Fernández; Laura I Furlong; Emre Guney; Jan A Kors; Miguel Angel Mayer; Manuel Pastor; Janet Piñero; Juan Manuel Ramírez-Anguita; Francesco Ronzano; Philip Rowell; Josep Saüch-Pitarch; Alfonso Valencia; Bob van de Water; Johan van der Lei; Erik van Mulligen; Ferran Sanz
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.